CN1292778C - Chinese medicine composition for stopping itching and its preparing method - Google Patents
Chinese medicine composition for stopping itching and its preparing method Download PDFInfo
- Publication number
- CN1292778C CN1292778C CNB2004100501355A CN200410050135A CN1292778C CN 1292778 C CN1292778 C CN 1292778C CN B2004100501355 A CNB2004100501355 A CN B2004100501355A CN 200410050135 A CN200410050135 A CN 200410050135A CN 1292778 C CN1292778 C CN 1292778C
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- medicine composition
- grams
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title abstract description 7
- 230000007803 itching Effects 0.000 title description 5
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 10
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 9
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 8
- 208000010247 contact dermatitis Diseases 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000001139 anti-pruritic effect Effects 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000169121 Toxicum Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 241000700199 Cavia porcellus Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 10
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 229960003291 chlorphenamine Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- -1 tabletting Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
- 238000012850 discrimination method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229930014456 matrine Natural products 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 229940032024 DPT vaccine Drugs 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010046742 Urticaria contact Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 235000020995 raw meat Nutrition 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- ZSBXGIUJOOQZMP-BHPKHCPMSA-N sophoridine Chemical compound C1CC[C@@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-BHPKHCPMSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LGDFHDKSYGVKDC-UHFFFAOYSA-N 8-hydroxyquinoline-5-sulfonic acid Chemical group C1=CN=C2C(O)=CC=C(S(O)(=O)=O)C2=C1 LGDFHDKSYGVKDC-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KOECRLKKXSXCPB-UHFFFAOYSA-K triiodobismuthane Chemical compound I[Bi](I)I KOECRLKKXSXCPB-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses an itch stopping Chinese medicine composition which is prepared with nine kinds of Chinese medicine materials, including rehmannia root, angelica sinensis, Radix Sophorae Flavescentis, cortex dictamni, red sage roots, periostracum cicadae, Radix Glycyrrhizae, Radix Scutellariae and Rhizoma Smilacis Glabrae. The itch stopping Chinese medicine composition has the efficacy of nourishing the blood, moistening dryness, expelling dampness, eliminating toxicum, dispelling wind and stopping an itch, and can treat skin pruritus, eczema or contact dermatitis. The present invention also discloses a preparing method and an identifying method of the medicine.
Description
Invention field
The present invention relates to a kind of itching relieving Chinese medicine composition, the present invention also relates to the preparation method and the discrimination method of this Chinese medicine composition.
Background technology
" Drug Standard of Ministry of Public Health of the Peoples Republic of China (the 16 in Chinese traditional patent formulation preparation) " is Radix Rehmanniae, Radix Angelicae Sinensis, Radix Sophorae Flavescentis, Cortex Dictamni, Radix Salviae Miltiorrhizae, Periostracum Cicadae, Radix Glycyrrhizae, Radix Scutellariae and Rhizoma Smilacis Glabrae in the raw material that December in 1998 disclosed medicine of the present invention on the 31st, but amounts of components openly.The raw material that the inventor is better or best with curative effect is selected with measure feature, thereby has finished the present invention.
Goal of the invention
The purpose of this invention is to provide the littler Chinese medicine composition of a kind of antipruritic better efficacy side effect.
Another object of the present invention provides the preparation method of this Chinese medicine composition.
Another purpose of the present invention provides the discrimination method of this Chinese medicine composition.
Summary of the invention
Medicine of the present invention is made up of effective ingredient and/or pharmaceutically acceptable excipient, and wherein said effective ingredient is to be made by the raw material of Chinese medicine of following percentage by weight consumption:
Radix Rehmanniae 16-25%, Radix Angelicae Sinensis 13-20%, Radix Sophorae Flavescentis 13-20%, Cortex Dictamni 13-20%, Radix Salviae Miltiorrhizae 7-13%, Periostracum Cicadae 3-9%, Radix Glycyrrhizae 3-9%, Radix Scutellariae 1-7% and Rhizoma Smilacis Glabrae 1-7%.
In order to obtain better therapeutic, the consumption of preferred raw material of Chinese medicine is following percentage by weight: Radix Rehmanniae 18-22%, Radix Angelicae Sinensis 14-18%, Radix Sophorae Flavescentis 14-18%, Cortex Dictamni 14-18%, Radix Salviae Miltiorrhizae 8-12%, Periostracum Cicadae 4-8%, Radix Glycyrrhizae 4-8%, Radix Scutellariae 2-6% and Rhizoma Smilacis Glabrae 2-6%.
In order to obtain optimum curative effect, more preferably the consumption of raw material of Chinese medicine is following percentage by weight:
Radix Rehmanniae 21%, Radix Angelicae Sinensis 16%, Radix Sophorae Flavescentis 16%, Cortex Dictamni 16%, Radix Salviae Miltiorrhizae 10%, Periostracum Cicadae 6.5%, Radix Glycyrrhizae 6.5%, Radix Scutellariae 4% and Rhizoma Smilacis Glabrae 4%.
The method for preparing effective ingredient of the present invention can be the raw material drying with above-mentioned consumption, pulverizes mixing; Also can be with above-mentioned raw materials extracting section or all extractions.For example take by weighing Radix Rehmanniae, Radix Angelicae Sinensis, Radix Sophorae Flavescentis, Cortex Dictamni, Radix Salviae Miltiorrhizae, Periostracum Cicadae, Radix Glycyrrhizae, Radix Scutellariae, the Rhizoma Smilacis Glabrae of above-mentioned consumption, directly with the dry levigation of raw material of Chinese medicine difference, mixing is made powder.Also above-mentioned raw material of Chinese medicine can be extracted and refining carry or the 60-80% ethanol extraction, reclaim or concentrated, make various dosage forms such as capsule, tablet, granule, oral liquid etc. with pharmaceutically acceptable excipient as water.
Preferably take by weighing Radix Rehmanniae, Radix Angelicae Sinensis, Radix Sophorae Flavescentis, Cortex Dictamni, Radix Salviae Miltiorrhizae, Periostracum Cicadae, Radix Glycyrrhizae, Radix Scutellariae, the Rhizoma Smilacis Glabrae of above-mentioned consumption, Radix Scutellariae, Rhizoma Smilacis Glabrae powder are broken into fine powder, seven flavors such as all the other Radix Rehmanniae decoct with water 2-4 time, and 1-3 hour for the first time, 0.5-2 hour for the second time, collecting decoction, filter, it is the clear paste of 1.10-1.15 that filtrate is concentrated into 70-80 ℃ of survey relative density, adds 1-4 and doubly measures ethanol, fully stir, leave standstill, the leaching supernatant reclaims ethanol, concentrating under reduced pressure becomes thick paste, add above-mentioned powder, mixing, drying, be ground into fine powder, encapsulated.
This invention medicine has blood enriching and dryness moistening, removing dampness detoxifcation, the effect of dispelling wind for relieving itching.Can be used for treating skin pruritus and belong to that blood deficiency is wet accumulates skin card person.Oral, a 1.5g～2.0g.
1, with Drug therapy 82 examples of the present invention, the total effective rate person reaches 91.15%, prove skin pruritus, and eczema (acute attack stage), contact dermatitis has significant curative effect.
2, medicine of the present invention reaches 90.91% to skin pruritus effective percentage 95.84% to eczema (acute attack stage) effective percentage, and the contact dermatitis effective percentage is reached 93.06%, learns by statistics and handles, and there were significant differences (p＜0.0001).
3, medicine of the present invention offsets except that skin is scratched where it itches, flushing or glad red and rotten to the corn infiltration all have and disappear preferably or the improvement effect.
4, all dialectical back of case medication, wherein blood-heat type, damp-heat type effective percentage all reach 100%, and blood-dryness type effective percentage 75%, and damp-obstruction type 100% case is invalid proves by medicine of the present invention to be not suitable for being used to distinguish patient into the dampness type.
5, take medicine of the present invention and do not see what toxic reaction is arranged, and take effect rapidly.
The discrimination method of medicine of the present invention comprises the following steps:
A) get discriminating medicine 0.5g, add methanol 10ml, warm macerating 10 minutes filters, and filtrate evaporate to dryness, residue add methanol 1ml makes dissolving, as need testing solution.Other gets matrine and sophoridine reference substance and adds methanol respectively and make the solution that every 1ml contains 1mg, in contrast product solution.According to " the thin layer chromatography test of an appendix VI of Chinese pharmacopoeia version in 2000 B, draw above-mentioned need testing solution 5 μ l, each 3 μ 1 of reference substance solution, put respectively on same silica gel g thin-layer plate, with chloroform-methanol of 5: 0.5: 0.1-strong ammonia solution is developing solvent, launch, take out, dry, spray is with rare bismuth iodide clock test solution; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the fluorescence speckle of same color;
B) get and differentiate medicine 1g, add hydrochloric acid 1ml and chloroform 20ml, reflux 1 hour is put coldly, and divide and get chloroform layer, filtration, filtrate evaporate to dryness, residue add ethanol 1ml makes dissolving, as need testing solution.Other is extracting liquorice control medicinal material 0.1g, shine medical material solution in pairs with legal system, according to " the thin layer chromatography test of an appendix VI of Chinese pharmacopoeia version in 2000 B, draw need testing solution 5 μ l and control medicinal material solution 3 μ l, put respectively on same silica gel g thin-layer plate, with 10: 20: 7: 0.5 30-60 ℃ petroleum ether-benzene-ethyl acetate-glacial acetic acid was developing solvent, launch, take out, dry, spray is with 0.5: 5 the 8% vanillin alcoholic solution and the mixed liquor of sulfuric acid solution, and it is clear that hot blast blows to the speckle colour developing; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show identical 1～2 yellow to the orange colour speckle;
C) get discriminating medicine porphyrize, precision takes by weighing 1g, adds ethanol 30ml, water-bath refluxed 30 minutes, put cold back and filter, use ethanol 15ml, divide the washing filtering residue three times, merging filtrate and washing liquid, evaporate to dryness, residue is also quantitatively transferred in the 5ml measuring bottle with dissolve with methanol, adds methanol and is diluted to scale, shake up, as need testing solution.Other dry 24 hours the matrine reference substance of phosphorus pentoxide of learning from else's experience is an amount of, accurately claims surely, adds methanol and makes the solution that every 1ml contains 1mg, in contrast product solution.According to " the thin layer chromatography test of an appendix VI of Chinese pharmacopoeia version in 2000 B, the accurate need testing solution 4-8 μ l that draws, reference substance solution 2 μ l and 4 μ l, respectively the cross point in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with 4: 3: 2: ethyl acetate-acetone of 0.2-benzene-ammonia was developing solvent, launch, take out, dry, spray covers onesize glass plate with rare bismuth potassium iodide test solution on lamellae, use immobilization with adhesive tape on every side, according to " test of an appendix VI of Chinese pharmacopoeia version in 2000 B thin-layer method scans wavelength: λ S=525nm, λ R=650nm, measure test sample trap integrated value and reference substance trap integrated value, calculate, every 0.5g differentiates that medicine contains matrine and must not be less than 0.70mg.
Specific embodiment
Embodiment 1: capsular preparation
Take by weighing Radix Rehmanniae 620 grams, Radix Angelicae Sinensis 480 grams, Radix Sophorae Flavescentis 480 grams, Cortex Dictamni 480 grams, Radix Salviae Miltiorrhizae 280 grams, Periostracum Cicadae 180 grams, Radix Glycyrrhizae 180 grams, Radix Scutellariae 115 grams and Rhizoma Smilacis Glabrae 115 grams, Radix Scutellariae, Rhizoma Smilacis Glabrae powder is broken into fine powder, and seven flavors such as all the other Radix Rehmanniae decoct with water twice, 3 hours for the first time, 2 hours for the second time, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.10-1.15 (70-80 a ℃), add 2 times of amount ethanol, fully stir, leave standstill the leaching supernatant, reclaim ethanol, concentrating under reduced pressure becomes thick paste, adds above-mentioned powder, mixing, dry, be ground into fine powder, encapsulated, make 1000 altogether.Trade name claims the noxious dampness clearing capsule again.
Embodiment 2: the preparation of tablet
Take by weighing Radix Rehmanniae 580 grams, Radix Angelicae Sinensis 500 grams, Radix Sophorae Flavescentis 500 grams, Cortex Dictamni 500 grams, Radix Salviae Miltiorrhizae 320 grams, Periostracum Cicadae 220 grams, Radix Glycyrrhizae 180 grams, Radix Scutellariae 100 grams and Rhizoma Smilacis Glabrae 100 grams, Radix Scutellariae, Rhizoma Smilacis Glabrae powder are broken into fine powder, and seven flavors such as all the other Radix Rehmanniae decoct with water twice, collecting decoction, be condensed into thick paste, add above-mentioned powder and granulate drying, granulate, add magnesium stearate, tabletting, coating is made 1000 altogether.
Embodiment 3: the preparation of granule
Take by weighing Radix Rehmanniae 630 grams, Radix Angelicae Sinensis 400 grams, Radix Sophorae Flavescentis 400 grams, Cortex Dictamni 400 grams, Radix Salviae Miltiorrhizae 240 grams, Periostracum Cicadae 160 grams, Radix Glycyrrhizae 160 grams, Radix Scutellariae 110 grams and Rhizoma Smilacis Glabrae 90 grams; decoct with water twice; 3 hours for the first time; 2 hours for the second time; collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.10-1.15 (70-80 a ℃); add 2 times of amount ethanol; fully stir, leave standstill the leaching supernatant; reclaim ethanol; be condensed into the clear paste of 1.10-1.15 (70-80 ℃), add dextrin, granulate with a step comminutor; drying is packetized into 1000 bags.
Embodiment 4: the preparation of granule
Take by weighing Radix Rehmanniae 250 grams, Radix Angelicae Sinensis 120 grams, Radix Sophorae Flavescentis 160 grams, Cortex Dictamni 120 grams, Radix Salviae Miltiorrhizae 60 grams, Periostracum Cicadae 30 grams, Radix Glycyrrhizae 30 grams, Radix Scutellariae 15 grams and Rhizoma Smilacis Glabrae 40 grams; add 70% alcohol reflux 2～3 times; each 1.5～3 hours; reclaim ethanol; be condensed into the clear paste of 1.10-1.15 (70-80 ℃), add dextrin, granulate with a step comminutor; drying is packetized into 1000 bags.
Embodiment 5: the preparation of tablet
Take by weighing Radix Rehmanniae 160 grams, Radix Angelicae Sinensis 180 grams, Radix Sophorae Flavescentis 120 grams, Cortex Dictamni 180 grams, Radix Salviae Miltiorrhizae 65 grams, Periostracum Cicadae 80 grams, Radix Glycyrrhizae 60 grams, Radix Scutellariae 40 grams and Rhizoma Smilacis Glabrae 15 grams, decoct twice jointly, collecting decoction, be condensed into thick paste, add starch and granulate, add magnesium stearate, tabletting, coating.
Embodiment 6: capsular preparation
Take by weighing Radix Rehmanniae 180 grams, Radix Angelicae Sinensis 110 grams, Radix Sophorae Flavescentis 140 grams, Cortex Dictamni 160 grams, Radix Salviae Miltiorrhizae 60 grams, Periostracum Cicadae 30 grams, Radix Glycyrrhizae 80 grams, Radix Scutellariae 10 grams and Rhizoma Smilacis Glabrae 40 grams, all the other are with embodiment 1.
Embodiment 7: capsular preparation
Take by weighing Radix Rehmanniae 220 grams, Radix Angelicae Sinensis 140 grams, Radix Sophorae Flavescentis 110 grams, Cortex Dictamni 140 grams, Radix Salviae Miltiorrhizae 100 grams, Periostracum Cicadae 80 grams, Radix Glycyrrhizae 30 grams, Radix Scutellariae 60 grams and Rhizoma Smilacis Glabrae 15 grams, all the other are with embodiment 1.
The pharmacodynamics test of test example 1 medicine of the present invention
Experiment material:
1, tried thing and medicine: (1), test sample are the medicated powder of medicine of the present invention, and every gram medicated powder is equivalent to crude drug 5.20g, and lot number is 960410, and Yulin Pharmaceutic Factory, Gangxi Autonomous Region's (promptly showing Yulin Pharmaceutical Co., Ltd., Guangxi) provides; (2), chlorphenamine, Kunming pharmaceutical factory production, lot number is 941105; (3), WUSHE ZHIYANG WAN, Guangzhou No.1 Chinese Pharmacy Factory production, lot number is 94080053; (4), histamine, Shanghai Inst. of Biochemistry, Chinese Academy of Sciences; (5), dextran (low molecule), Jiangsu Huanghai Sea pharmaceutical factory, lot number is 94100202; (6), dimethyl sulfoxine, chemical reagent factory in Rugao produces, analytical pure, lot number 940802; (7), DPT vaccine, Wuhan Biological Products Inst., Ministry of Public Health produces, lot number 950431-6; (8), azovan blue, Shanghai chemical reagent purchasing and supply station, Fluka import packing, lot number 82-11-02; (9), sodium cromoglicate, Qianjiang City, Hubei pharmaceutical factory, lot number 9409012; (10), hydrocortisone, 25mg/5ml, Hubei Pharmaceutic Works, lot number 940408.
2, animal: Kunming mouse, regular grade body weight 18～24g, Guangxi district epidemic prevention station animal housing provides; The Wistar rat, regular grade, body weight 150～350g, institute of oncology, Guangxi animal housing provides; Cavia porcellus, body weight 200～300g, animal housing of Guangxi Medical University provides.The animal male and female are all used.
Experimental technique and result:
One, to the effect of drug-induced animal skin pruritus
1, dextran is caused the influence of mouse skin pruritus
50 of mices, divide 5 groups at random: (1) blank group (distilled water 20ml/kg, ig); (2) the chlorphenamine matched group (4mg/kg, ig); (3) (2g/kg in pill weight, descends together, ig) the WUSHE ZHIYANG WAN matched group; (4) (4.5g/kg in the crude drug amount, descends together, ig) medicine low dose group of the present invention; (5) medicine high dose group of the present invention (9g/kg, ig).Each organizes mice respectively ig administration or distilled water 1 time, and behind the 30min, iv dextran 1 .25mg/kg write down the total degree and the lasting total time of every mice pruritus outbreak in 20 minutes.
The result shows that medicine of the present invention has obvious itching-relieving action to the mouse skin pruritus due to the dextran, sees Table 1.With the blank group significant difference (P＜0.01) is arranged relatively.
Table 1 medicine of the present invention causes the influence (X ± SD) of mouse skin pruritus to dextran
| Group | Dosage | Number of animals | The pruritus number of times | The pruritus persistent period |
| Blank chlorphenamine WUSHE ZHIYANG WAN medicine of the present invention medicine of the present invention | 4mg/kg 2g/kg 4.5g/kg 9g/kg | 10 10 10 10 10 | 29.8±6.6 6.1±3.6 *** 12.7±6.1 *** 25.2±4.6 * 21.2±3.6 *** | 163.5±30.0 10.1±3.3 *** 34.0±15.6 *** 65.8±33.6 *** 55.7±30.1 *** |
Do t check, * P＞0.05, * * * P＜0.01 with the blank group
2, histamine is caused the influence of Cavia porcellus pruritus
40 of Cavia porcelluss, hair is shaved on right instep behind every Cavia porcellus, and uses the sand paper scratch mark, the about 1cm of area
2, animal is divided 5 groups at random subsequently: and (1) blank group (distilled water 10ml/kg, ig); (2) the chlorphenamine matched group (4mg/kg, ig); (3) the WUSHE ZHIYANG WAN matched group (1g/kg, ig); (4) medicine low dose group of the present invention (2.3g/kg, ig); (5) medicine high dose group of the present invention (4.5g/kg, ig).Every Cavia porcellus gastric infusion 1 time, after 30 minutes, right sufficient wound surface drips 0.01% histamine liquid in the back, after this complied with 0.01%, 0.02%, 0.03%, 0.04% every 3 minutes ... progressive concentration, only be 0.05ml/ at every turn, directly causing and Cavia porcellus occurs and later lick the right foot in back, is itch-threshold with the histamine total amount that occurs at last being given when Cavia porcellus later licks the right foot in back.
The result shows that medicine 4.5g/kg dosage group of the present invention can obviously improve itch-threshold, sees Table 2.With the blank group significant difference (P＜0.01) is arranged relatively.
Table 2 medicine of the present invention causes the influence (X ± SD) of Cavia porcellus pruritus to histamine
| Group | Dosage | Number of animals | Itch-threshold (histamine total amount, μ g) |
| Blank chlorphenamine WUSHE ZHIYANG WAN medicine of the present invention medicine of the present invention | 4mg/kg 1g/kg 2.3g/kg 4.5g/kg | 8 8 8 8 8 | 55.0±95.1 247.9±46.4 *** 171.0±106.7 ** 145.0±103.4 * 218.3±87.8 *** |
Make t check, * P＞0.05, * * P＜0.05, * * * P＜0.0l with the blank group
Two, medicine of the present invention causes the effect of non-immunity contact urticaria to dimethyl sulfoxine
40 of Cavia porcelluss, divide 5 groups at random: (1) blank group (distilled water 10ml/kg, ig); (2) the chlorphenamine matched group (4mg/kg, ig); (3) the WUSHE ZHIYANG WAN matched group (1g/kg, ig); (4) medicine low dose group of the present invention (2.3g/kg, ig); (5) medicine high dose group of the present invention (4.5g/kg, ig).Each organizes every Cavia porcellus gastric infusion 1 time, after 30 minutes, be coated with 80% dimethyl sulfoxine (dehydrated alcohol preparation), 50 μ l outside the auris dextra two sides, after this in 1 hour, 3 hours thickness with 4 points of vernier caliper measurement auricle, obtain meansigma methods, deduct the outer meansigma methods that is coated with preceding 4 points of dimethyl sulfoxine, difference is a Cavia porcellus auricle edema value.
The result shows that medicine 4.5g/kg dosage group of the present invention causes the non-immunity contact urticaria to dimethyl sulfoxine antagonism, sees Table 3.With the blank group significant difference (P＜0.05) is arranged relatively.
Table 3 medicine of the present invention is to (the X ± SD) of the bullate influence of Cavia porcellus ear due to the dimethyl sulfoxine
| Group | Dosage | Number of animals | Auricle edema value (10 -3，mm) | |
| 1 hour | 3 hours | |||
| Blank chlorphenamine WUSHE ZHIYANG WAN medicine of the present invention medicine of the present invention | 4mg/kg 1g/kg 2.3g/kg 4.5g/kg | 8 8 8 8 8 | 140.0±88.1 50.6±36.9 ** 60.0±37.9 ** 90.8±40.6 * 51.4±37.6 ** | 55.7±23.0 20.6±18.9 ** 31.7±26.4 ** 40.1±20.6 * 28.6±23.4 ** |
Do t check, * P＞0.05, * * P＜0.05, * * * P＜0.01 with the blank group
Three, medicine of the present invention is to the effect of rat passive cutaneous anaphylaxis, PCA of the same race
Get 4 of female rats, im5% Ovum Gallus domesticus album normal saline 0.5ml, ip immunological adjuvant DPT vaccine 2 * 10 simultaneously
10Individual/only, blood sampling after 12 days, preparation rat ovaserum.
Other gets 40 of rats, divides 5 groups at random: and (1) blank group (distilled water 10ml/kg, ig); (2) the sodium cromoglicate matched group (25mg/kg, ig); (3) the WUSHE ZHIYANG WAN matched group (1g/kg, ig); (4) medicine low dose group of the present invention (2.3g/kg, ig); (5) medicine high dose group of the present invention (4.5g/kg, ig).Each organizes the ovaserum 0.1ml of every rat back subcutaneous injection through dilution in 1: 5, the while gastric infusion, every day 1 time, continuous 3 times, after the art time administration 1 hour, be to carry out antigen after the sensitization in 48 hours to attack tail vein injection 5% Ovum Gallus domesticus album (0.5ml/100g) and 1% azovan blue normal saline (0.5ml/100g); Put to death animal after 30 minutes, the skin of back locus coeruleus is cut and shredded place 5ml normal saline---acetone (3: 7) mixed liquor, place after 24 hours, get supernatant and measure optical density value (OD) in the 610nm place.
The result shows that all reaction has significant inhibitory effect to medicine high and low dose group of the present invention to models of passive skin irritability of rats, sees Table 4.With the blank group significant difference (P＜0.05) is arranged relatively.
Table 4 medicine of the present invention is to the influence of passive cutaneous anaphylaxis, PCA (X ± SD)
| Group | Dosage | Number of animals | Optical density value | Suppression ratio (%) |
| Blank sodium cromoglicate WUSHE ZHIYANG WAN medicine of the present invention medicine of the present invention | 25mg/kg 1g/kg 2.3g/kg 4.5g/kg | 8 8 8 8 8 | 0.081±0.019 0.006±0.002 *** 0.041±0.010 *** 0.062±0.016 ** 0.057±0.015 ** | 92.6 49.4 23.5 29.6 |
Do t check, * * P＜0.05, * * * P＜0.01 with the blank group
Test example 2
Case is selected:
Allly be diagnosed as the skin disease (general or limitation) of itching. allergic dermatitis (contain contact dermatitis. drug eruption etc.). eczema (acute stage) and have flushing, glad red, scratch where it itches, symptom such as rotten to the corn infiltration or person wherein, all belong to this range of observation.
Diagnosis basis:
Eczema (acute attack stage)
1, flushing or glad red, scratch where it itches, rotten to the corn infiltration etc., last desquamation and healing;
2, easily betide two, symmetry is arranged more; Edible fish raw meat stimulating food is toward firmly making state of an illness aggravation;
3, alleviate easily, increase the weight of or recur, the border is generally not clear.Contact dermatitis:
1, certain article (containing medicine) contact history or anaphylactogen contact history are arranged;
2, outbreak is unexpected, and the General Symptoms weight differs, common heating, headache, vomiting etc.;
3, flushing or glad red appears in the part, and burning sensation is arranged, and scratches where it itches, and it is mashed etc. that the broken back eliminating dampness by diuresis of large carbuncle(disease) is wasted; Also can be the welt sample, the erythema multiforme sample causes change etc.
Skin pruritus (general or limitation):
1, part or whole skin pruritus can move to another place by a place on health, itch night very;
2, various frictions and cold, warm stimulation all can cause the pruritus outbreak, and the time of at every turn scratching where it itches was not waited by several branch kinds to a few hours.
3, pruritus varying degree is scratched until local damage hemorrhagely because of firmly grabbing when serious, and symptom just alleviates gradually.
4, be more common in the old people, normal being sent out in autumn and winter season.
Medicine typing:
Damp-heat type: skin lesion flushing, chickenpox, erosion, stream are grown, the border is filled the air, and acutely scratch where it itches, accompany uncomfortable in chest indigestion and loss of appetite, constipation with dry stool, yellowish or reddish urine, yellowish fur, slippery and rapid pulse etc.
Blood-heat type: skin lesion is based on erythema, pimple, scratch, blood crusts, acute pruritus, and desquamation is few, often with xerostomia red tongue, thready and rapid pulse etc.
Damp-obstruction type: the skin lesion color is dark, and light red or not red, chickenpox is few, but exudation, normal doublely sees anorexia, shallow complexion, and just few, tongue is greasy in vain, and soft pulse is sliding etc.
Blood-dryness type: outbreak repeatedly, touching difficulty more doublely see that health becomes thin light red tongue, soft and thready pulse etc.(this typing refers to acute attack stage eczema more, skin pruritus, allergic dermatitis etc. can with reference to this standard typing) physical data:
This group patient 82 examples, male's 43 examples wherein, women's 39 examples; Age is in 7 examples below 15 years old, 16-30 year person's 26 examples, 31-45 year 17 examples, 46-65 year 19 examples, 13 examples more than 66 years old; Clinical diagnosis belongs to skin pruritus 32 examples, contact dermatitis 24 examples, acute eczema acute attack person 22 examples, other 4 example.Differentiation of symptoms and signs for classification of syndrome belongs to blood-heat type 19 examples, damp-heat type 44 examples, blood-dryness type 16 examples, damp-obstruction type 3 examples; Clinical symptoms shows as skin hectic fever or glad red person 72 examples, the person's of scratching where it itches 76 examples, honest and clean mashed infiltration person's 30 examples.
Therapeutic Method:
Matched group is not established in this observation, treatment group clothes " medicine of the present invention " capsule, and every day 3 times, each 3-4 grain, 7 days is a course of treatment, serve on 2-3 the course of treatment, symptom does not have the improver after 3 courses of treatment, makes invalidation.
Viewing duration diet raw meat, acid, peppery, and cigarette, wine etc. have the zest article.
Efficacy assessment standard:
Cure: clinical symptoms is eliminated, recidivist more not in three months.
Produce effects: clinical symptoms is obviously improved or is eliminated, recurrence in three months after the drug withdrawal, but obtain obvious improvement or eliminator again through the clinical symptoms of taking medicine again.
Effectively: kind due to symptom after taking medicine has.
Invalid: take medicine full three the course of treatment symptom do not have the improver.
Therapeutic outcome:
This group is cured 33 examples, produce effects 23 examples, effective 19 examples, invalid 7 examples, total effective rate 91.15%.Wherein skin pruritus 32 examples are cured 14 examples, produce effects 9 examples, effective 5 examples, invalid 4 examples, effective percentage 87.5%; Contact dermatitis 24 examples are cured 11 examples, produce effects 5 examples, effective 7 examples, invalid 1 example, effective percentage 95.84%; Eczema 22 examples are cured 6 examples, produce effects 8 examples, effective 6 examples, invalid 2 examples, effective percentage 90.91%.
Erubescence Cheng Xinre person 72 examples, through treatment resolution of symptoms person 52 examples, improver's 15 examples, no changer's 5 examples, effective percentage reaches 93.06%; Skin itching person 76 examples, through treatment resolution of symptoms person 34 examples, the person's of making moderate progress 33 examples, no changer's 9 examples, effective percentage 88.16%, skin erosion person 30 examples, symptom eliminator 19 examples wherein, the person's of making moderate progress 8 examples, no changer's 3 examples, effective percentage 90%.
Dialectical genus blood-heat type 19 examples are wherein cured 8 examples, produce effects 5 examples, effective 6 examples, effective percentage 100%; Damp-heat type 44 examples are wherein cured 20 examples, produce effects 19 examples, effective 5 examples, effective percentage 100%; Blood-dryness type 16 examples are wherein cured 2 examples, produce effects 5 examples, effective 5 examples, invalid 4 examples, effective percentage 75%; Damp-obstruction type 3 examples are all invalid.
Claims (9)
1. an antipruritic Chinese medicine composition is made up of effective ingredient and/or pharmaceutically acceptable excipient, and wherein said effective ingredient is made by following raw materials by weight percent:
Radix Rehmanniae 16-25%, Radix Angelicae Sinensis 13-20%, Radix Sophorae Flavescentis 13-20%, Cortex Dictamni 13-20%, Radix Salviae Miltiorrhizae 7-13%, Periostracum Cicadae 3-9%, Radix Glycyrrhizae 3-9%, Radix Scutellariae 1-7% and Rhizoma Smilacis Glabrae 1-7%.
2. according to the described Chinese medicine composition of claim 1, wherein the raw material consumption is:
Radix Rehmanniae 18-22%, Radix Angelicae Sinensis 14-18%, Radix Sophorae Flavescentis 14-18%, Cortex Dictamni 14-18%, Radix Salviae Miltiorrhizae 8-12%, Periostracum Cicadae 4-8%, Radix Glycyrrhizae 4-8%, Radix Scutellariae 2-6% and Rhizoma Smilacis Glabrae 2-6%.
3. according to the described Chinese medicine composition of claim 2, wherein the raw material consumption is:
Radix Rehmanniae 21%, Radix Angelicae Sinensis 16%, Radix Sophorae Flavescentis 16%, Cortex Dictamni 16%, Radix Salviae Miltiorrhizae 10%, Periostracum Cicadae 6.5%, Radix Glycyrrhizae 6.5%, Radix Scutellariae 4% and Rhizoma Smilacis Glabrae 4%.
4. according to any one described Chinese medicine composition among the claim 1-3, it is capsule, tablet, granule or oral liquid.
5. claim 1 or 2 or 3 described Chinese medicine composition preparation methoies, the preparation method that it is characterized in that effective ingredient is for taking by weighing raw material, Radix Scutellariae, Rhizoma Smilacis Glabrae powder are broken into fine powder, seven flavors such as all the other Radix Rehmanniae decoct with water 2-4 time, 1-3 hour for the first time, 0.5-2 hour for the second time, collecting decoction, filter, it is the clear paste of 1.10-1.15 that filtrate is concentrated into 70-80 ℃ of survey relative density, adds 1-4 and doubly measures ethanol, fully stirs, leave standstill, the leaching supernatant reclaims ethanol, and concentrating under reduced pressure becomes thick paste, add above-mentioned powder, mixing.
6, Chinese medicine composition preparation method according to claim 5, it is characterized in that taking by weighing raw material, Radix Scutellariae, Rhizoma Smilacis Glabrae powder are broken into fine powder, and seven flavors such as all the other Radix Rehmanniae decoct with water 2-4 time, 1-3 hour for the first time, 0.5-2 hour for the second time, collecting decoction filters, and it is the clear paste of 1.10-1.15 that filtrate is concentrated into 70-80 ℃ of survey relative density, add 1-4 and doubly measure ethanol, fully stir, leave standstill the leaching supernatant, reclaim ethanol, concentrating under reduced pressure becomes thick paste, adds above-mentioned powder, mixing, be ground into fine powder, encapsulated.
7, claim 1 or 2 or 3 described Chinese medicine composition preparation methoies; it is characterized in that taking by weighing raw material; add 70% alcohol reflux 2～3 times; each 1.5～3 hours, reclaim ethanol, being condensed into 70-80 ℃ of survey relative density is the clear paste of 1.10-1.15; add acceptable accessories; granulate with a step comminutor, drying is made granule or capsule or tablet.
8, any one described Chinese medicine composition is preparing the purposes for the treatment of the skin pruritus disease medicament among the claim 1-4.
9, any one described Chinese medicine composition is preparing the purposes for the treatment of skin pruritus, eczema or contact dermatitis medicine among the claim 1-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100501355A CN1292778C (en) | 2004-06-28 | 2004-06-28 | Chinese medicine composition for stopping itching and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100501355A CN1292778C (en) | 2004-06-28 | 2004-06-28 | Chinese medicine composition for stopping itching and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714840A CN1714840A (en) | 2006-01-04 |
| CN1292778C true CN1292778C (en) | 2007-01-03 |
Family
ID=35821201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100501355A Ceased CN1292778C (en) | 2004-06-28 | 2004-06-28 | Chinese medicine composition for stopping itching and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1292778C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5729936B2 (en) * | 2009-07-31 | 2015-06-03 | 株式会社 資生堂 | Screening method for chronic inflammation inhibitor or cancer metastasis inhibitor using inhibition of binding between empurin and S100A9 as an index |
| CN103505535B (en) * | 2012-06-29 | 2015-05-06 | 北大方正集团有限公司 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
| CN103830425B (en) * | 2014-03-27 | 2015-10-28 | 蚌埠火鹤制药有限公司 | Traditional Chinese medicine for treating blood deficiency type skin itch |
| CN103990051A (en) * | 2014-05-22 | 2014-08-20 | 四川金堂海纳生物医药技术研究所 | Traditional Chinese medicine preparation for treating damp toxin and preparation method thereof |
| CN105106067A (en) * | 2015-09-11 | 2015-12-02 | 金玛瑙香水（明光）有限公司 | Health care perfume for adjusting estrogen level of human body and improving skin xerosis |
| CN105301167A (en) * | 2015-11-02 | 2016-02-03 | 成都九芝堂金鼎药业有限公司 | Quality control method for lung-tonifying pills |
| CN110038099A (en) * | 2018-01-15 | 2019-07-23 | 杨凤仪 | A kind of preparation method for treating refractory skin medicament |
| CN111281952A (en) * | 2018-12-07 | 2020-06-16 | 上海中医药大学附属龙华医院 | A kind of traditional Chinese medicine composition for dehumidification and itching and its preparation method and use |
-
2004
- 2004-06-28 CN CNB2004100501355A patent/CN1292778C/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1714840A (en) | 2006-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102153668B (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN1292778C (en) | Chinese medicine composition for stopping itching and its preparing method | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN109718273A (en) | Perilla leaf extract is preventing or is treating the application in Osteoarthritis | |
| CN1233378C (en) | Chinese medicine composition for treating oral cavity and throat diseases and its preparing method | |
| CN1303098C (en) | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine | |
| CN103405494A (en) | Bauhinia championii n-butyl alcohol extract and preparation method and application thereof | |
| CN1762455A (en) | Chinese medicinal formulation for treating infant lung and stomach exuberance heat | |
| CN1316990C (en) | Chinese medicinal composition, preparation method and quality control method thereof | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN102406694A (en) | Anti-tumor effective part of traditional Chinese medicine lespedeza as well as preparation method and application thereof | |
| CN1299757C (en) | Chinese medicinal composition for treating scapulohumeral periarthritis and preparing method thereof | |
| CN102813873A (en) | Traditional Chinese medicine composition for treating mental diseases, and preparation method, application and quality control thereof | |
| CN1899410A (en) | Medicine for treating cardiovascular disease and its preparing method and quality control method | |
| CN1241586C (en) | Chinese medicine composition and preparing method thereof | |
| CN108219024B (en) | Calophyllum inophyllum flower polysaccharide, extraction method thereof and application thereof in preparing medicine for treating functional constipation | |
| CN1220510C (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method | |
| CN1799564A (en) | Application of valeriana wallichii and its extract in preparation of medicine for treating anxiety neurosis | |
| CN1814025A (en) | Detoxification and itching-relieving medicine composition and preparing method | |
| CN101040899A (en) | Antineoplastic Chinese traditional compound and the preparation and the method for producing the same | |
| CN1314424C (en) | Traditional Chinese medicine for treating liver cancer and preparation process thereof | |
| CN1923263A (en) | Traditional Chinese medicine composition, its preparing method and quality controlling means | |
| CN103585580A (en) | Chinese medicinal preparation for treating recurrent oral ulceration | |
| CN1931296A (en) | Pinellia tuber extract and its prepn process, medicine composition and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C35 | Partial or whole invalidation of patent or utility model | ||
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20091029 Decision number of declaring invalidation: 14008 Granted publication date: 20070103 |
|
| C56 | Change in the name or address of the patentee |
Owner name: GUANGXI YULIN PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: YULIN PHARMACEUTICAL CO., LTD., GUANGXI |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 537001 No. 1 Station Road, the Guangxi Zhuang Autonomous Region, Yulin Patentee after: GUANGXI YULIN PHARMACEUTICAL GROUP Co.,Ltd. Address before: 537001 No. 1 Station Road, the Guangxi Zhuang Autonomous Region, Yulin Patentee before: Guangxi Yulin Pharmaceutical Co.,Ltd. |
|
| CI01 | Publication of corrected invention patent application |
Correction item: invalidation announcement of patent right Correct: Cancel all invalid notice False: All invalid announcement Number: 28 Volume: 28 |
|
| ERR | Gazette correction |